Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies
A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History
Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production
THOUSAND OAKS, Calif., Oct.
U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Inovio Pharmaceuticals, MedImmune and the University of Pennsylvania Partner to Combat Influenza and Antibiotic Resistant Bacteria
Fidelity Biosciences and Atlas Venture Lead $12 Million Series A Funding to Launch Unum Therapeutics, a New Cellular Immunotherapy Company
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
Editor Note: For more information about this release, please scroll to bottom.
LONDON, October 20, 2014